Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) EBITDA (2016 - 2025)

Historic EBITDA for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to -$3.7 million.

  • BioRestorative Therapies' EBITDA fell 6217.85% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.5 million, marking a year-over-year decrease of 2007.52%. This contributed to the annual value of -$11.6 million for FY2024, which is 2408.27% up from last year.
  • As of Q3 2025, BioRestorative Therapies' EBITDA stood at -$3.7 million, which was down 6217.85% from -$3.3 million recorded in Q2 2025.
  • In the past 5 years, BioRestorative Therapies' EBITDA ranged from a high of -$2.3 million in Q3 2024 and a low of -$15.1 million during Q1 2021
  • Over the past 5 years, BioRestorative Therapies' median EBITDA value was -$3.7 million (recorded in 2025), while the average stood at -$4.4 million.
  • As far as peak fluctuations go, BioRestorative Therapies' EBITDA tumbled by 173820.0% in 2021, and later soared by 6643.04% in 2022.
  • Over the past 5 years, BioRestorative Therapies' EBITDA (Quarter) stood at -$4.0 million in 2021, then decreased by 16.78% to -$4.7 million in 2022, then surged by 31.21% to -$3.2 million in 2023, then increased by 16.47% to -$2.7 million in 2024, then plummeted by 37.87% to -$3.7 million in 2025.
  • Its EBITDA was -$3.7 million in Q3 2025, compared to -$3.3 million in Q2 2025 and -$4.8 million in Q1 2025.